Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

2.

[Role of the new molecules in antiretroviral therapy. Position of raltegravir].

Arribas JR.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:53-9. Review. Spanish.

PMID:
19572427
3.

Treatment strategies for highly treatment-experienced HIV-infected patients.

Luber AD.

Expert Rev Anti Infect Ther. 2005 Oct;3(5):815-23. Review.

PMID:
16207173
4.

Tipranavir.

Temesgen Z, Cainelli F, Vento S.

Drugs Today (Barc). 2005 Nov;41(11):711-20. Review.

PMID:
16395412
5.

An update and review of antiretroviral therapy.

Piacenti FJ.

Pharmacotherapy. 2006 Aug;26(8):1111-33. Review.

PMID:
16863488
6.

Tipranavir: a review of its use in the management of HIV infection.

Orman JS, Perry CM.

Drugs. 2008;68(10):1435-63. Review.

PMID:
18578560
8.

Tipranavir: a new option for the treatment of drug-resistant HIV infection.

Temesgen Z, Feinberg J.

Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. Review.

PMID:
17712762
9.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
10.

Tipranavir: a ritonavir-boosted protease inhibitor.

Croom KF, Keam SJ.

Drugs. 2005;65(12):1669-77; discussion 1678-9. Review.

PMID:
16060700
11.

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Luna B, Townsend MU.

Clin Ther. 2007 Nov;29(11):2309-18. Review.

PMID:
18158073
12.

Management of HIV-infected patients with multidrug-resistant virus.

Harris M, Montaner JS.

Curr HIV/AIDS Rep. 2004 Sep;1(3):116-21. Review.

PMID:
16091231
13.

Clinical perspective of fusion inhibitors for treatment of HIV.

Rockstroh JK, Mauss S.

J Antimicrob Chemother. 2004 May;53(5):700-2. Epub 2004 Mar 24. Review.

PMID:
15044424
14.

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

Kaplan SS, Hicks CB.

J Antimicrob Chemother. 2005 Aug;56(2):273-6. Epub 2005 Jun 30. Review.

PMID:
15994247
15.
16.

Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.

Cervia JS, Smith MA.

Clin Infect Dis. 2003 Oct 15;37(8):1102-6. Epub 2003 Sep 10. Review.

PMID:
14523775
17.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
18.

Tipranavir.

Plosker GL, Figgitt DP.

Drugs. 2003;63(15):1611-8. Review.

PMID:
12887268
19.

Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.

Clotet B.

AIDS Rev. 2004 Jul-Sep;6(3):123-30. Review.

PMID:
15595429
20.

The fusion inhibitor enfuvirtide in recent antiretroviral strategies.

Makinson A, Reynes J.

Curr Opin HIV AIDS. 2009 Mar;4(2):150-8. doi: 10.1097/COH.0b013e32832498d8. Review.

PMID:
19339955

Supplemental Content

Support Center